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Atherosclerosis, the primary cause of Coronary Heart Disease (CHD), has become one of
the top causes of death in the world. As low-density lipoprotein (LDL) particles become
trapped and oxidized inside arterial walls, the primary oxidation products of 1-palmitoyl2-arachidonyl-sn-glycerol-3-phosphatidylcholine (PAPC) induce the binding of
monocytes which can potentially lead to fatty plaque build ups. A fragment of one of
these oxidation products, OxPAPC, has previously been studied and can act as standard
for testing new phospholipids and how they affect protein expression levels. The central
hypothesis of this study was that three newly studied classes of oxidized fatty acids
exhibit distinct control patterns over specific genes involved in inflammation. The genes
of interest are crucial at various points in the pathway: monocyte recruitment (MCP-1),
inflammation (IL-8), and oxidative stress regulation (HO-1). Previous studies have shown
that other molecules belonging to these classes of fatty acids are able to downregulate
certain genes in the inflammation pathway for human aortic endothelial cells (HAECs),
likely leading to decreased inflammation levels. The effects of these three groups of
novel oxidized fatty acids known as isoprostanes, neuroprostanes, and neurofurans, were
investigated and tested to see if there was potential for biological pathway control and
identify effects of fatty acid structure on biological activity in HAECs. This research will
assist in the development of future treatments for atherosclerosis and CHD.
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INTRODUCTION
The primary goal of this Master’s thesis was to further understanding of the mechanism
through which oxidized fatty acids exert control on the inflammatory pathway genes in human
aortic endothelial cells. This was accomplished through defining and understanding the effect of
lipid chemistry on regulation of pathways in atherosclerosis. This research will contribute to the
development of novel treatments for coronary heart disease and, potentially, other chronic
inflammatory diseases.

Importance of Chronic Inflammation/Atherosclerosis Research
Cardiovascular disease is the leading cause of death in fully modernized countries and is
on the rise in developing countries. The most recent data shows that cardiovascular disease has
claimed approximately 630,000 lives in 2016, accounting for 1 in every 4 deaths.1
Atherosclerosis is the underlying condition in coronary heart disease (CHD), which involves the
accumulation and hardening of fatty deposits on the inside of arterial walls, forming masses that
restrict the flow of blood and potentially leading to severe adverse events, such as heart attack
and stroke. Certain risk factors, such as smoking, poor diet, and high blood pressure can
predispose people to be more at risk for developing atherosclerosis.2

Relation to Coronary Heart Disease
Atherosclerosis can occur in any artery inside the body, including but not limited to, the
heart, brain, legs, and arms. The main issue is that organs that can be affected by the disease
require oxygen-rich blood for proper functioning. Coronary heart disease (CHD), also known as
coronary artery disease, occurs when plaque deposits inside of the coronary arteries of the heart
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which can lead to various number of diseases if untreated. A pictorial example of this blocking
of arteries is shown in figure 1.

Figure 1. Normal Artery versus Partially Blocked Artery Due to Plaque Build-Up3

On the left-hand side of Figure 1, normal artery physiology is shown where no significant
amounts of plaque are present and blood flow is unrestricted. As for the right side, plaque buildup is shown which allows for a substantial decrease in the volumetric flow rate of blood that can
be allowed through. When referring to specific examples of diseases that can arise from the
above pathophysiology, one set of examples are angina and myocardial infarction, otherwise
known as chest pain and a heart attack. When the crucial arteries that supply blood to the heart
are blocked, there is increased risk of more serious conditions such as heart attack or stroke, both
of which can cause morbidity or mortality.4
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Current Treatments
Presently, there are a number of treatment regimens available for people affected by
CHD. These treatment plans include heart healthy eating, maintaining a healthy weight for a
given age and height, stress management, as well as physical activity. The goal of these plans is
to affect the formation of plaques at the arterial level. This is accomplished through the following
overarching points: lowering risk of blood clot formation, preventing development/complications
of CHD, reducing risk factors inherent to certain individuals, relieving already present
symptoms, as well as widening or bypassing already clogged arteries.5 Outside of activity-based
lifestyle changes, there are also pharmaceutical treatment options that are available. Statins,
medications that alter cholesterol concentrations by inhibiting cholesterol production by the
body, can cause a decrease in the amount of plaque deposition on coronary arteries. Other
medications available are aspirin, beta blockers, calcium channels blockers, and nitroglycerin
tablets. More serious methods of treatments involve surgical intervention. Recent procedures that
have had fairly significant clinical success are angioplasty/stent placement and coronary artery
bypass surgery.6 While each of these options are viable depending on the stage of blockage that
is present in the coronary arteries, future novel treatments must be developed in order to combat
the increasing prevalence of heart disease and decrease necessity of surgery, which carries its
own risks and cost. In order for this to happen, research science must gain a better grasp on how
atherosclerosis works mechanistically.

3

LITERATURE REVIEW

This literature review will focus on previous research that focused on elucidating how
oxidized fatty acids regulate atherosclerosis. Research topics covered in the past that were
analyzed are: current theory of atherosclerosis pathophysiology, oxidized phospholipid roles in
atherosclerosis, and currently understood role of oxidized fatty acids in atherosclerosis.

Proposed Theory
Recent studies have shown that the formation of atherosclerosis begins with either
endothelial injury or by a significant accumulation of low-density lipoprotein (LDL) particles
along the inside of the arterial wall. LDL particles may also be oxidatively modified. Once these
LDL particles are modified, they take on the form known as minimally modified low density
lipoproteins (MM-LDL). Varying levels of inflammation brought about by endothelial injury
causes the body to trigger both an innate and adaptive immune response.7 Figure 2 shows a
simplified representation of how these arterial fatty streaks form in the initial stages of the plaque
development.
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Figure 2. Atherosclerotic Inflammation Pathway Diagram8

As seen above, during the development of atherosclerosis, LDL particles pass through the
arterial wall and become “trapped” LDL as they undergo oxidation in addition to becoming MMLDL. These MM-LDL particles contain oxidation products of 1-palmitoyl-2-arachidonyl-snglycero-3-phosphocholine (Ox-PAPC), as well as other oxidized phospholipids.9 Referring to the
monocyte recruitment pathway, interleukin 8 (IL-8) and monocyte chemotactic protein (MCP-1)
are genes that have both been shown to become upregulated in endothelial cells in the presence
of Ox-PAPC.10 MCP-1 is a potent monocyte attractant as well as a member of the CC chemokine
family. These chemokines are those with adjacent cysteine amino acid residues near the Nterminus of their protein structure, aiding in their targeting of monocytes as well as T-cells in the
body. During inflammation, MCP-1 plays a crucial role in the recruitment of monocytes in order
to alleviate infections or in this case, accumulation of oxidized lipids.11 IL-8 is classified as a
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chemoattractant cytokine which aids in the recruitment of neutrophils, a type of white blood
cell.12 In regions where inflammation occurs, IL-8 is produced by a variety of cell types due to
inflammatory stimuli and in some studies, has been shown to aid in the recruitment of rolling
monocytes onto the arterial wall to combat atherosclerotic lesion formation.13 Another protein of
interest that will be looked at is heme oxygenase-1 (HO-1) which has been shown to exhibit
immunosuppressant effects in response to oxidative stress. HO-1 is believed to be involved in
this process due to these anti-inflammatory effects. At this point in the pathway, the oxidized
LDL particles lead to endothelial dysfunction by attracting monocytes as well as T cells to
adhere to the interior of the artery wall, potentially forming foam cells, and eventually fatty,
atherosclerotic streaks.14 These fatty streaks may eventually progress to advanced lesions which
often lead to further decrease in the volumetric flow of blood through the artery..

Overview of Ox-PAPC, PEIPC, and EI
The research set forth in this thesis was focused on Ox-PAPC and its major oxidative
components. Of the oxidized biomolecules present in Ox-PAPC, one of the most prolific and
activity enhancing is 1-palmitoyl-2-(5,6-epoxyisoprostane E2)-sn-glycero-3-phosphorylcholine
(PEIPC) and is shown below in Figure 3.15

Figure 3. PEIPC Chemical Structure16
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As shown in multiple studies, PEIPC is a potent inducer of monocyte binding during
chronic inflammation. One study in particular involved the collection of endothelial cell cultures
from 149 different heart transplant donors. 149 HAEC cultures were obtained from aortic
explants of the aforementioned donors and grown to an appropriate confluency level. Significant
activity was noted for the cells treated with oxidized phospholipid, including Ox-PAPC and
PEIPC. The allylic epoxide group on PEIPC is thought to be the major activity site for the
molecule which lends to increased monocyte binding.17 Microarray analysis showed that of the
2000 genes in question for the study, over 1000 were regulated by Ox-PAPC and at least 80% of
these were controlled by PEIPC.18

As critical as oxidized phospholipids are for regulation of inflammation, recent studies
have shown what may prove to be a key mediator for oxidized phospholipid activity in the form
of phospholipases. These phospholipases impact the activity of oxidized phospholipids through
hydrolysis of the oxidized fatty acid or the functional head group. This reaction results in the
formation of lysophospholipids, phosphatidic acids, and other oxidized fatty acids. Cleavage at
each site requires a specific phospholipase. A summary of this activity modulation reaction can
be seen below in Figure 4.19
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Figure 4. Oxidized Phospholipid Cleavage by Phospholipases19

A specific case study of this phospholipase activity involved the culture of HAECs and
subsequent treatment with oxidized phospholipids, including PEIPC, that had themselves been
treated with snake venom phospholipase A2 (PLA2). The results of the study showed that the
introduction of PLA2 decreased PEIPC’s capability to stimulate monocyte binding.20 When
treated with PLA2, the phospholipase reaction produces four regioisomers of PEIPC, the most
active of the four is hypothesized to be 5,6-epoxyisoprostane (EI). The reaction and subsequent
product can be seen in Figure 5.18

Figure 5. Phospholipase Reduction of PEIPC to EI
8

From the above previous study that looked at the synthesis of the four analogue structures
of EI and their respective effects on genes of interest, Figure 6 shows the structure of each
enantiomer of EI, including EI4, which data showed was the most biologically active of the
stereoisomers in HAEC as measured by regulation of IL-8, HO-1 and MCP-1.18

Figure 6: Structure of EI Analogues18

Working from previous research that hinted at the importance of EI and its relation to
Ox-PAPC and PEIPC in terms of activity, the main hypothesis was that EI would exhibit similar
activity levels to PEIPC, be more feasible in terms of synthesis for future studies, and also act as
a more stable oxidizing molecule. In relation to the work of this thesis, the effects of EI4 were
not directly tested but should be confirmed in future work on the subject. EI4 and PEIPC showed
a 5-fold decrease and a 13-fold increase in MCP-1 mRNA levels, respectively. These treatments
also resulted in a 3.0-fold increase in IL-8 mRNA for EI4 and a 17-fold increase for PEIPC.
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Finally, these treatments also resulted in a 15-fold increase in HO-1 mRNA from EI treatment
while PEIPC showed around a 10-fold increase. EI the compound downregulated eight other
inflammatory molecules in HAEC, potentially increasing the likelihood that it is involved as an
anti-inflammatory regulator. It is vital to look at the effects of EI on IL-1, which is a cytokine
that has been shown to accumulate in atherosclerotic lesions in mice. When this cytokine has
been knocked out, atherosclerosis levels decrease in research settings. Results from this study
have shown that EI was able to successfully inhibit IL-1. From these results, it is clear that with
respect to certain genes involved in the inflammation pathway, EI and PEIPC regulate similar
pathways, but EI shows anti-inflammatory effects, whereas PEIPC often upregulates
inflammatory pathways.18

Newly Studied Fatty Acids
The purpose of this thesis was to validate and expand previous work results for oxidized
lipids, providing a stronger research foundation for future endeavors into the pathway and its
intricacies. In this research, regulation of the inflammatory pathway (IL-8), the oxidative stress
pathway (HO-1) and the monocyte binding pathway (MCP-1) by an isoprostane, a
neuroprostane, and a neurofuran will be compared to regulation by EI. Isoprostanes are
molecules produced as a result of free radical damage to arachidonic acid (AA), which is a fatty
acid that is heavily distributed throughout both the white and grey matter of the brain. Shown
below in Figure 7 is the specific isoprostane that was used in this study.21
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Figure 7: Isoprostane from AA

Neuroprostanes are created in an analogous manner from the molecule docosahexaenoic
acid (DHA). In contrast to AA, DHA is mostly present in the grey matter where its main
concentration lies in neurons of the region. It has been hypothesized that neuroprostanes may be
more sensitive biomarkers for damage caused by free radicals due to DHA being more prone to
peroxidation than its counterpart AA. Figure 8 shows the neuroprostane that was involved in this
study.21

Figure 8: Neuroprostane from DHA

Similarly to neuroprostanes, neurofurans are derived from DHA and can be used as
biomarkers to test for levels of oxidative damage in certain areas of the body where these
molecules are concentrated. One caveat of these DHA derived molecules is that using them as
biomarkers is currently more complicated than using a molecule derived from AA because DHA
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is more unsaturated than AA. Shown below in Figure 9 is the neurofuran that was tested in this
thesis.22

Figure 9: Neurofuran from DHA

The use of isoprostanes and neuroprostanes in the detection of neurological diseases,
such as Alzheimer’s disease, is currently on the rise as the synthesis rate of these molecules in
the brain is noticeably increased when the disease is present.23 More work is currently being
done in the field of neurofurans to if detection of these fatty acids can be detected early enough
and used as a risk factor measurement.

MAIN OBJECTIVES

Building on the above-mentioned work, the goal of this research was to further elucidate
the mechanism by which oxidized fatty acids, including neurofurans, neuroprostanes, and
isoprostanes, affect inflammation in HAECs. This objective was accomplished through the
treatment of HAECs with the novel fatty acids and the use of RT-PCR to determine which gene
levels are upregulated or downregulated by each treatment. Because the effects of neurofurans,
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neuroprostanes, and isoprostanes have not been extensively studied, the results achieved from
these molecules were compared to OxPAPC regulation.

Broader Impact
The broader impact of this thesis was to aid in the understanding of how atherosclerosis
functions mechanistically. Uncovering this mechanism required experimental data that
demonstrated how novel oxidized fatty acids influence inflammation in HAECs, further
expanding on previous research in the field. Acquiring this data has served two main purposes: to
compare against previous research data acquired in other studies and to act as a comparison
against the data for the oxidized fatty acids that have not been tested to date in other work.
Overall, the long-term goal of this project will be to help future research efforts to be able to
develop more efficient treatment plans for patients affected by atherosclerosis or even reveal
potential novel biomarkers for coronary heart disease.

Experimental Methods
The purpose of this experimental methods section is to detail techniques used in the
treatment of HAECs with oxidized fatty acids as well as the subsequent data collection methods
and procedures. To determine the effect of oxidized fatty acids on inflammation levels for
HAECs, several techniques were employed. The HAECs had to be grown to an appropriate level
of confluency on tissue culture plates and then treated with 3 µM isoprostane, neuroprostane, or
neurofuran. The goal of this stage was to measure gene expression levels based on specific
treatments, while comparing fatty acid regulation with previous results. For lipid treatment, the
standard exposure time of HAECs to each lipid is approximately 4 hours, but this time was
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altered as needed to ensure optimal results. Each 6 well treatment plate was split up into three
groups: the first being control (no lipid treatment), the second with 20 µM Ox-PAPC, and the
final group with 3 µM of one of the three oxidized fatty acid types of interest. Once the treatment
time had lapsed, the cells were exposed to an RNA lysis solution to lyse the cells. From here the
RNA were extracted and the concentration was determined to know if enough exists for cDNA
preparation in the next step. Finally, RT-PCR was employed to determine the genetic regulation
effect of the fatty acids on GAPDH (normalization gene), MCP-1, IL-8, and HO-1. The results
obtained for the novel oxidized fatty acids (isoprostanes, neuroprostanes, and neurofurans) were
compared to collected results for OxPAPC to show if they are involved in upregulation or
downregulation of the above genes, and by what magnitude.

METHODOLOGY

The purpose of this methodology is to outline the experimental procedures used to meet
the research objectives set forth in this thesis. This section will include the following sections:
materials and reagents, endothelial cell culture growth, oxidized fatty acid treatment, RNA
extraction and cDNA synthesis, and RT-PCR.

Materials and Reagents
HAECs and Fetal Bovine Serum (FBS) were purchased through Thermo Scientific.
Media 199 (M199) was purchased through MediaTech. RNA Primers for GAPDH, MCP-1, IL-8,
and HO-1 were purchased through Integrated DNA Technologies. OxPAPC used during
experimental procedures was synthesized beforehand using organic chemistry methods and was
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used in the procedure of a previous publication.18 The three types of novel oxidized fatty acids
used were synthesized and provided to us by collaborators at Institut des Biomolecules Max
Mousseron (IBMM) (Jean-Marie Galano and Thierry Durand).

HAEC Culture Growth
This section will detail the procedure of growth and transfer of HAECs between
appropriate growth and treatment settings. To begin with, 100 mm tissue culture dishes were
coated with 5 mL of premade gelatin solution (need concentration) along the entire bottom of the
plate to create a scaffolding for cells to later adhere to. Once allowed to incubate at 37 oC for ~30
minutes, the gelatin was aspirated and the plates were washed with 10 mL of Phosphate Buffer
Solution (PBS) and appropriately mixed. The PBS was aspirated, and the plates were then filled
with 19 mL of endothelial cell basal medium (ECBM) to provide a nutrient source for the
HAECs. Cells (known as Passage 1 or P1 cells) were then transferred in 1 mL of ECBM to the
100 mm plate and sufficiently spread out, ensuring the cells were not overly agitated.

HAEC Passage Splitting
Once HAECs had approached a critical level of confluency, the present ECBM was
aspirated from the 100 mm plate. The cells were washed with 10 mL of PBS and then aspirated.
Using a 1:3 dilution rate, a trypsin/PBS solution was created, and 3 mL were applied to each
plate in order to remove the cells from their scaffolding. Trypsin is an enzyme that cleaves
attachment proteins on the cells, allowing for lifting and transfer. After appropriate washing
with the trypsin/PBS solution, the 3 mL of cell solution was transferred to a 15 mL test vial and
placed in the centrifuge at a speed of 1000 rpm for approximately 10 minutes. The residual
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media supernatant above the cell pellet was subsequently aspirated and the remaining pellet was
rinsed with 1 mL of ECBM for each plate that the cells would be split to. Most often a 1:3
splitting was desired, so from the previous passage of n number, 3n next passage plates would be
produced until passage 5 or 6 was reached, depending on confluency levels.

HAEC Treatment with Oxidized Fatty Acids
This section explains how cells were treated with oxidized fatty acid once the appropriate
passage number was achieved and cells were transferred to 6 well plates. HAECs were washed
with PBS a total of three times, which was followed by treatment with 3 µM EI, 20 µM OxPAPC, or 3 µM isoprostane/neuroprostane/neurofuran in M199 medium containing 1% FBS for
four hours.9 HAECs will be later washed with PBS, lysed in order to extract the RNA, and RTPCR analysis was run.

Real-Time Polymerase Chain Reaction
For RT-PCR analysis, the 7900HT Sequence Detector System model was utilized.
Complete RNAs from the HAECs was extracted from the fatty acid treated cells using the Total
RNA extraction procedure from the modified Bio-rad protocol. cDNA synthesis was performed
using the Applied Biosciences kit. The SYBR® green master mix bought from ThermoFisher
was used in PCR quantification and amplification. For the genes being measured in the PCR
analysis, GAPDH was measured to normalize mRNA as well as fold change levels of the other
genes between both treated and untreated cells. Each specific primer sequence used in the qPCR
analysis was as follows:
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GAPDH Forward: 5′ - CCT CAA GAT CAT CAG CAA TGC CTC CT - 3′, Reverse: 5′ - GGT
CAT GAG TCC TTC CAC GAT ACC AA - 3′; HO-1: Forward: 5′ - ATA GAT GTG GTA
CAG GGA GGC CAT CA - 3′, Reverse: 5′ - GGC AGA GAA TGC TGA GTT CAT GAG GA 3′; IL-8: Forward: 5′ - ACC ACA CTG CGC CAA CAC AGA AAT - 3′, Reverse: 5′ - TCC
AGA CAG AGC TCT CTT CCA TCA GA - 3′: Forward: 5′ - ACT CTC GCC TCC AGC ATG
AA - 3′, Reverse: 5′ - TTG ATT GCA TCT GGC TGA GC – 3’.

PREVIOUS EXPERIMENTAL RESULTS

Referring back to work completed by previous graduate students, a trend of expected
results can be obtained to use as a measure for any experimental readouts. The data sets were
divided into four main groups, gene regulation levels for OxPAPC, isoprostane, neuroprostane,
and neurofuran. For each of these lipids, regulation of MCP-1, IL-8, and HO-1 mRNA levels
will be measured.

Gene Regulation by Novel Oxidized Fatty Acids in HAECs
The next three data sets focus on the effect on MCP-1, IL-8, and HO-1 by the novel
oxidized fatty acids in the form of isoprostane, neuroprostane, and neurofuran. Through these
data sets, it is the hope of this thesis that more information can be deduced about the chemical
pathways and reasoning behind the function of oxidative stress in inflammation. Figures 11
through 13 summarize the results of the three groups and their effects on mRNA fold change
levels.
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Figure 10. Previous Results from 3µM Isoprostane Treatment Testing Gene Regulation
Levels of HAECs

Figure 10 serves to graphically represent regulation of MCP-1, HO-1 and IL-8 mRNA
levels by the isoprostane in HAECs, named 15-F21-IsoP (C20H34O5). Both MCP-1 and HO-1
show minimal increases in fold change with values of 1.06 and 1.10 respectively. IL-8, however
saw an incredibly significant increase in fold change with an associated value of 3.06. In the
above graph, the double asterisk will represent a p-value less than 0.01, but the single asterisk is
indicative of a p value less than 0.05. This value of 0.05 is still able to reject the null hypothesis,
but with less statistical significance. These results may be indicative of certain isoprostanes
upregulating inflammatory (IL-8), oxidative stress (HO-1) and monocyte recruitment (MCP-1)
gene pathways in HAECs.
18

Figure 11. Previous Results from 3µM Neuroprostane Treatment Testing Gene Regulation
Levels of HAECs

Figure 11 shows gene regulation levels for the neuroprostane, named 4-epi-4-F31-NeuroP
(C22H36O5) has on the mRNA fold change levels of the three genes of interest. MCP-1 mRNA
was upregulated by 1.41-fold in HAECs while both HO-1 and IL-8 were both downregulated,
with fold changes 0.90 and 0.62, respectively after neuroprostane treatment.
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Figure 12. Previous Results from 3µM Neurofuran Treatment Testing Gene Regulation
Levels of HAECs

Figure 12 shows gene regulation levels for the neuroprostane, named 4-epi-4-F31-NeuroP
(C22H36O5) has on the mRNA fold change levels of the three genes of interest. HO-1 mRNA
levels were significantly upregulated by neuroprostane treatment of HAEC, with a fold change of
1.14, while both MCP-1 and IL-8 were downregulated, with fold changes of 0.63 and 0.71,
respectively.
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EXPERIMENTAL RESULTS

Using the methodology outlined above, the effects of the three types of oxidized fatty
acids on the inflammatory pathway were observed in HAECs and validated using two methods.
First, the effects of OxPAPC and its subsequent up- or downregulation of the three proteins must
be considered. The reasoning for analyzing OxPAPC along with the lipid and control wells is to
ascertain whether the results are valid based on previous research which shows the appropriate
effects of OxPAPC on the expression levels. From previous work, it has been shown that
OxPAPC upregulates both HO-1 and IL-8 but downregulates MCP-1. Based on this the results
can be given an extra measure of their validity.

Calculation Methods
Working into the second validation method, it is necessary to explain how both the fold
change levels were calculated as well as the p-value. GAPDH was analyzed along with HO-1,
IL-8, and MCP-1 for the purpose of being a housekeeper gene. This specific gene acts as the
control baseline from which the other value can subtract this baseline to yield the true fold
change expression levels. This was completed with the following data points obtained through
the 7900HT Sequence Detector System and is shown in equations one through three.
ΔCt = Average Ct Value of Sample – Average Ct Value of GAPDH

(1)

ΔΔCt = ΔCt Experiment – ΔCt Control

(2)

Ψ (Fold Change of mRNA Levels) = 2(-ΔΔCt)

(3)
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The average Ct value is the average cycle number where the fluorescence created from
the PCR reaction goes beyond the fluorescence threshold.24 This subtracted from the GAPDH
average cycle number, as mentioned above, gives a more realistic idea of when this number
occurs for the gene in question. The Ct Experiment and Ct Control are the ΔCt values for samples
treated with lipid and those that were not, respectively. Finally, the fold change level represents
how much the lipid causes the up- or downregulation of the specific gene when normalized
against the control sample.
After figuring out the fold change levels, the second method of result validation is
utilized in the form of the p-value method. The p-value is the calculated probability of the null
hypothesis of a given experiment being found true. For most cases, the null hypothesis, Ho is a
statement of no difference. This means that there is no significant difference between the data
sets of two (or more) groups.25 For this thesis, Ho is that there is no significant difference
between the control level of fold change regulation and the levels for the lipids being tested.
Using a 95% confidence interval, is the p-value for the experiment is less than 0.05, then this is a
rejection of Ho. This means that there is statistically significant difference between the control
and lipid results. Calculation of the p-value was accomplished through the two sample T-test
shown below in equations four through seven.
d.f. = n1 + n2 – 2

(4)

(𝑛1 −1)𝑠12 +(𝑛2 −1)𝑠22

sp = √

𝑡=

(5)

𝑛1 +𝑛2 −2

𝛹1 −𝛹2

(6)

1
1
𝑠𝑝 √𝑛 +𝑛
1
2

p-value = TDIST(t-test, d.f., number of tails)

(7)
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As shown above, n is the number of duplicate samples for a given test set. sp is the
standard deviation which was calculated by the 7900HT Sequence Detector System. Equations
six and seven yield the t-test and subsequent p-value for each experiment. From the graphs that
follow, a single asterisk above a result bar is indicative of a p-value less than 0.10 (rejection of
Ho if the confidence interval was 90%). A double asterisk symbol above a test result bar
indicates the p-value was below 0.05 and the result was statistically significant, rejecting Ho.

Results
For the isoprostane molecule tested in this thesis, the results obtained were relatively
similar to previous work as shown below in Figure 13.
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Figure 13. Control and Lipid Results from 3µM Isoprostane Treatment Testing Gene
Regulation Levels of HAECs
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All three proteins aw slight upregulation compared to the control wells, with IL-8
showing the highest level of upregulation among them. The p-values for HO-1, IL-8, and MCP-1
were 0.0659, 0.0048, and 0.2388 respectively. This indicates that the results for HO-1 are
significant, but the results for IL-8 and MCP-1 were not able to say with certainty that they are
statistically significant. The issue with this data set however, comes in the form of how OxPAPC
expression levels with the three proteins resulted. Both HO-1 and IL-8 saw upregulation as was
expected, however, MCP-1 also showed significant upregulation which contradicts previously
established results and present a possible source of error for the isoprostane test results. This can
be seen graphically below in Figure 14.
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Figure 14. All Results from 3µM Isoprostane Treatment Testing Gene Regulation Levels of
HAECs

Next to discuss is the neuroprostane. When comparing the control wells to those treated
with neuroprostane, the results for HO-1 and IL-8 were near identical with only slight
upregulation being noted in both cases. In the case of MCP-1, there was significant down
regulation of the protein when the neuroprostane was present, indicating a potential for
regulation of the monocyte recruitment pathway. The p-values for this set were 0.2673, 0.4967,
and 0.0639, mimicking the trend from the isoprostane results for MCP-1 but giving different
interpretations for HO-1 and IL-8. The graphical results can be seen below in Figure 15.
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Figure 15. Control and Lipid Results from 3µM Neuroprostane Treatment Testing Gene
Regulation Levels of HAECs

When comparing the neuroprostane data for validity, the comparison of results against
OxPAPC seem to be slightly more valid than the isoprostane data. The tests show upregulation
for HO-1 and downregulation for MCP-1, which are consistent with previous findings, however
the issue comes when looking at IL-8 data. As seen in Figure 14, the levels shown in Figure 16
below show similar levels for HO-1 but the upregulation for IL-8 takes a moderate dip.

26

Fold Change of mRNA Levels

3
2.243
2.5

2

1.230

1.5

1.051
1.001
0.859

1

*
0.622
0.5

0
HO-1

IL-8
Control

OxPAPC

MCP-1
F8

Figure 16. All Results from 3µM Neuroprostane Treatment Testing Gene Regulation
Levels of HAECs

Finally, the expression level results for the neurofuran of interest must be noted. From
Figure 17, upregulation can be observed for both HO-1 and IL-8, while expression for MCP-1 is
downregulated, but not to a major extent. Again, looking to the p-values, the results were as
follows: 0.1678, 0.294, and 0.195. This set of p-values indicates that none of the protein
expression levels could be said to be statistically different from the control groups, bringing the
validity of the neuroprostane as a test article into question.
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Figure 17. Control and Lipid Results from 3µM Neurofuran Treatment Testing Gene
Regulation Levels of HAECs

Looking to Figure 18 for the control and OxPAPC levels compared to neurofuran
expression, the data is unique when compared with the other two lipids. Upregulation is noted
for all but MCP-1, suggesting potential for future experiments to see if the data skews any more
in the direction of downregulation or if this attempt was an outlier for the data.
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Figure 18. All Results from 3µM Neurofuran Treatment Testing Gene Regulation Levels of
HAECs

DISCUSSION
One of the main purposes of this thesis was to compare the results obtained from the
above set of experiments with previous work and see if the results are significantly similar. If
they are, then the results can be counted as replicates, further strengthening the results. If the
results contradict each other, then further sets of experiments mist be conducted to discern which
results are valid. Beginning with the isoprostane lipid results, previous work noted upregulation
for all three proteins, with the highest levels noted in IL-8. Across the board upregulation was
noted in current results, but the lowest levels of upregulation were noted for IL-8 instead of the
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highest. Potential reasons for this could be due to experimental variability due to human error or
outliers in the data that were not excluded from consideration. As mentioned previously, the
validity of the most recent results may be questionable due to the upregulation in IL-8 noted for
OxPAPC, but with the other two proteins agreeing with established results, further replicates
should be carried out to confirm or deny if the results are valid or a case of skewed data points.
Next to consider is the result comparison for the neuroprostane test set. For Previous results, HO1 and IL-8 showed downregulation while MCP-1 exhibited upregulation. Current results showed
polar opposite results in the form of HO-1 and IL-8 showing upregulation (incredibly small
margin for IL-8) while MCP-1 showed downregulation. At first glance, these results seem
invalid due to their drastic difference from previous work, but the comparison of OxPAPC
regulation levels is more consistent with established results, lending itself to the idea the current
results are valid. All this is to say that more experiments should be conducted into the
neuroprostane to see which way the results will tend toward.
Neurofuran results from previous work showed the trend of upregulation for HO-1 and
downregulation for both IL-8 and MCP-1. The current results agreed with HO-1 and MCP-1,
showing up- and downregulation respectively. Il-8 however showed opposite result, skewing
toward upregulation instead of down. OxPAPC comparison for current results agreed with
established values of upregulation for HO-1 and IL-8, and downregulation for MCP-1. This aids
in suggesting the current results are valid, once again, pointing to the fact that further
experimental repeats are warranted.
On an individual note, the issue regarding neurofuran p-values must be addressed. With
all three sets bearing substantially high p-values, the issue becomes figuring out where the
problem originates from. All three sets of genes in each set of experiments based on lipid, bore

30

approximately similar size error bars and each had their own issues where they did not agree
with the OxPAPC standard as much as they should have. A potential solution could be to limit
the window of data that is included for post experimental analysis, or to complete more sets of
experiments all together in conjunction with this to see if the issue subsides at all. As it currently
stands, the problem seems to be arising from outlier data points and further results should be
obtained to confirm or deny this hypothesis.
Overall, of the three sets of experiments conducted, none completely agreed on all three
protein levels with the previous work completed. For the results compared, on average two of the
three protein results would agree between past and present results. This is indicative that
previous results were valid to some degree, but further testing is required to make sure that the
results can be concretely confirmed.

FUTURE STUDIES
With the results of the effects of the three novel types of oxidized fatty acids having been
obtained, two main objectives still exist at this point. Reproduction of results to determine
experimental data validity is the first priority. If previous work and current results can agree on a
trend for the data, then further work can be continued to expand upon achieved results. Second,
work done on more oxidized fatty acids in the categories of isoprostanes, neuroprostanes, and
neurofurans need be considered to further demonstrate importance of these lipids in the
regulation of inflammation, also potentially contributing to the development of novel
therapeutics. With all of this in mind, this research will hopefully lead to the development of
novel treatments for heart disease in the future.
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